Pembrolizumab improves survival in non-squamous NSCLC

被引：0
|
作者：
不详
机构：
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：1306 / 1306
页数：1
相关论文
共 50 条
  • [1] THE EFFECT OF PEMETREXED CONTAINING REGIMES ON OVERALL SURVIVAL IN NON-SQUAMOUS NSCLC
    Stevens, R.
    Booth, H.
    Button, M.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S74 - S74
  • [2] Perioperative Pembrolizumab Improves Survival in Resected NSCLC
    Kim, Edward S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 370 - 371
  • [3] Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin plus /- Pembrolizumab in Metastatic Non-Squamous NSCLC
    Miller, J.
    Brown, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1084
  • [4] Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
    Surovtsova, Irina
    Herth, Felix J. F.
    Kokh, Daria B.
    Morakis, Philipp
    PULMONOLOGY, 2025, 31 (01):
  • [5] Maintenance Therapy in advanced non-squamous NSCLC With Pemetrexed a Survival Advantage can be achieved
    不详
    ONKOLOGIE, 2012, 35 (09):
  • [6] Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC
    Brown, J.
    Li, L.
    Moore, M.
    Moore, A.
    Desai, R.
    Gentzler, R.
    Balkrishnan, R.
    Hall, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S870 - S870
  • [7] NSCLC: Pembrolizumab improves progression-free survival
    Simon, Annika
    PNEUMOLOGIE, 2023, 77 (04):
  • [8] Necitumumab for patients with non-squamous NSCLC: uninspiring results
    Zhou, Fei
    Zhou, Caicun
    LANCET ONCOLOGY, 2015, 16 (03): : 246 - 247
  • [9] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
    Liu, Qiao
    Zhou, Zhen
    Luo, Xia
    Yi, Lidan
    Peng, Liubao
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [10] Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
    Insinga, Ralph P.
    Vanness, David J.
    Feliciano, Josephine L.
    Vandormael, Kristel
    Traore, Sory
    Burke, Thomas
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1191 - 1205
12345